United Therapeutics (UTHR) Q1 2024 Earnings
United Therapeutics reported Q1 2024 revenue of $677.7M, beat analyst consensus of $624.0M by $53.7M. Diluted EPS came in at $6.17, beat the $5.65 consensus by $0.52. United Therapeutics reports across 3 business segments, led by Pulmonary Hypertension and Rare Disease Therapies, Oncology, and Organ Manufacturing and Transplantation.
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about United Therapeutics's Q1 2024 earnings report.
United Therapeutics (UTHR) reported Q1 2024 earnings on May 1, 2024 before market open.
United Therapeutics reported revenue of $677.7M and diluted EPS of $6.17 for Q1 2024.
Revenue beat the consensus estimate of $624.0M by $53.7M. EPS beat the consensus estimate of $5.65 by $0.52.
You can read the 10-Q periodic report (0001082554-24-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.